文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

血脂异常。

Dyslipidemia.

机构信息

Johns Hopkins University School of Medicine, Baltimore, Maryland (M.A., C.J.L.).

出版信息

Ann Intern Med. 2023 Jun;176(6):ITC81-ITC96. doi: 10.7326/AITC202306200. Epub 2023 Jun 13.


DOI:10.7326/AITC202306200
PMID:37307585
Abstract

Dyslipidemia is an important risk factor for coronary artery disease and stroke. All persons with dyslipidemia should be advised to focus on lifestyle interventions, including regular aerobic exercise, a healthy diet, maintenance of a healthy weight, and abstinence from smoking. In addition to lifestyle interventions, lipid-lowering therapy should be considered for persons at moderate to high risk for atherosclerotic cardiovascular disease based on validated risk equations. Statin therapy is the first-line medical treatment for dyslipidemia due to its effectiveness and favorable adverse effect profile, but newer treatments provide additional tools for clinicians to effectively treat dyslipidemia.

摘要

血脂异常是冠心病和脑卒中的重要危险因素。所有血脂异常患者均应建议其注重生活方式干预,包括定期进行有氧运动、健康饮食、保持健康体重和戒烟。除生活方式干预外,还应根据经过验证的风险方程,考虑对存在动脉粥样硬化性心血管疾病中高危风险的患者进行降脂治疗。他汀类药物治疗由于其有效性和良好的不良反应谱,是血脂异常的一线治疗药物,但新型治疗方法为临床医生有效治疗血脂异常提供了更多手段。

相似文献

[1]
Dyslipidemia.

Ann Intern Med. 2023-6

[2]
Lipid-lowering therapy: who can benefit?

Vasc Health Risk Manag. 2011

[3]
Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.

Clin Ther. 2008-2

[4]
2017 Taiwan lipid guidelines for high risk patients.

J Formos Med Assoc. 2017-4

[5]
Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.

Am J Cardiovasc Drugs. 2005

[6]
Dyslipidemia and lipid-lowering therapy in the elderly.

Expert Rev Cardiovasc Ther. 2005-5

[7]
Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease.

Ann Vasc Surg. 2020-11

[8]
[Dyslipidemia, atherosclerosis, and vulnerable plaques: the effect of atorvastatin on atherosclerosis and plaque structure].

Turk Kardiyol Dern Ars. 2009-3

[9]
Practical recommendations for the management of cardiovascular risk associated with atherogenic dyslipidemia, with special attention to residual risk. Spanish adaptation of a European Consensus of Experts.

Clin Investig Arterioscler. 2017

[10]
Management of dyslipidemia with statins in the patient with peripheral arterial disease.

Tech Vasc Interv Radiol. 2006-6

引用本文的文献

[1]
Effect of folic acid and vitamin B12 plus rosuvastatin in the treatment of coronary heart disease combined with hyperlipidemia.

Front Cardiovasc Med. 2025-7-30

[2]
Dietary Habits and Obesity in Middle-Aged and Elderly Europeans-The Survey of Health, Ageing, and Retirement in Europe (SHARE).

Nutrients. 2025-7-31

[3]
Effects of soleus push-up exercise on systemic immune-inflammatory index and blood lipid profile in coronary artery disease.

Medicine (Baltimore). 2025-8-1

[4]
Non-linear association between the dietary index for gut microbiota and the atherogenic index of plasma: insights from a cross-sectional study.

Front Cardiovasc Med. 2025-7-4

[5]
Effects of vitamin E administration on serum lipid profile in diabetic patients: a grade-assessed systematic review and dose-response meta-analysis of RCTs.

Diabetol Metab Syndr. 2025-7-18

[6]
Effects of Personalized Nutrition Education on Lipid Profiles in Chinese Adults: A Medical Student-Implemented Community Intervention Study.

Nutrients. 2025-6-28

[7]
Shedding light on pharmacoepidemiology of eye diseases: a cohort study in Western Iran.

Sci Rep. 2025-7-9

[8]
Associations between dietary macronutrient quality and odds of hyperlipidemia: findings from the NEC-Biobank cohort.

Nutr J. 2025-7-7

[9]
Schisandrin C Improves Chronic Stress-Induced Dyslipidemia in Mice by Regulating Pyroptosis and Autophagy Levels.

J Microbiol Biotechnol. 2025-6-23

[10]
Current landscape of dyslipidemia-related randomized clinical trials registered on the International Clinical Trials Registry Platform.

Front Public Health. 2025-5-1

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索